AACR-话题@MedSci

#AACR#

120篇内容 | 3076人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1552047, encodeId=215b155204e6d, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR重磅之KGOG 3046/TRU-D：度伐利尤单抗和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的II期研究, objectType=article, longId=723985, objectId=b52ce23985ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b52ce23985ec, replyNumber=0, likeNumber=55, createdTime=2022-04-12, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b52ce23985ec, moduleTitle=AACR重磅之KGOG 3046/TRU-D：度伐利尤单抗和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b52ce23985ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552044, encodeId=6e5d1552044c6, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验, objectType=article, longId=723982, objectId=1388e239827e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1388e239827e, replyNumber=0, likeNumber=40, createdTime=2022-04-12, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1388e239827e, moduleTitle=AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1388e239827e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552050, encodeId=cbfe155205005, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, objectType=article, longId=723981, objectId=f235e2398163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f235e2398163, replyNumber=0, likeNumber=47, createdTime=2022-04-12, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f235e2398163, moduleTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f235e2398163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552046, encodeId=b2481552046dc, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR重磅：在化疗的基础上加用阿德雷利单抗可明显改善广泛期SCLC的一线治疗, objectType=article, longId=723970, objectId=9762e2397093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9762e2397093, replyNumber=0, likeNumber=77, createdTime=2022-04-12, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9762e2397093, moduleTitle=AACR重磅：在化疗的基础上加用阿德雷利单抗可明显改善广泛期SCLC的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9762e2397093)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552045, encodeId=58201552045bb, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, objectType=article, longId=723968, objectId=3207e2396893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3207e2396893, replyNumber=0, likeNumber=74, createdTime=2022-04-12, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3207e2396893, moduleTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3207e2396893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552036, encodeId=56cd1552036ef, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, objectType=article, longId=723967, objectId=4b52e23967b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b52e23967b8, replyNumber=0, likeNumber=81, createdTime=2022-04-12, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b52e23967b8, moduleTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b52e23967b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552035, encodeId=bc2d155203533, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR重磅：高基因扩增和肿瘤突变负荷组合作为接受替雷丽珠单抗治疗患者的泛癌生物标志物, objectType=article, longId=723965, objectId=ef58e23965b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef58e23965b0, replyNumber=0, likeNumber=75, createdTime=2022-04-12, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef58e23965b0, moduleTitle=AACR重磅：高基因扩增和肿瘤突变负荷组合作为接受替雷丽珠单抗治疗患者的泛癌生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef58e23965b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552034, encodeId=f9791552034ce, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究, objectType=article, longId=723964, objectId=100be239645b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=100be239645b, replyNumber=0, likeNumber=39, createdTime=2022-04-12, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=100be239645b, moduleTitle=AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=100be239645b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552033, encodeId=5ba2155203359, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR | 我国学者：97.17%的人至少是一种癌症的高风险人群，但坚持健康生活方式可明显降低风险!, objectType=article, longId=215296, objectId=708421529603, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=708421529603, replyNumber=0, likeNumber=61, createdTime=2021-08-06, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=708421529603, moduleTitle=AACR | 我国学者：97.17%的人至少是一种癌症的高风险人群，但坚持健康生活方式可明显降低风险!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=708421529603)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552032, encodeId=28e1155203212, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR年会：新辅助免疫治疗将NSCLC患者的病理完全反应率提高12倍！, objectType=article, longId=209948, objectId=f16820994893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f16820994893, replyNumber=0, likeNumber=93, createdTime=2021-04-15, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f16820994893, moduleTitle=AACR年会：新辅助免疫治疗将NSCLC患者的病理完全反应率提高12倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f16820994893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552031, encodeId=b4ee15520318d, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2021：NX-1607治疗结直肠癌和三阴性乳腺癌，临床前研究效果显著, objectType=article, longId=208270, objectId=d4122082e0e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4122082e0e1, replyNumber=0, likeNumber=83, createdTime=2021-03-13, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4122082e0e1, moduleTitle=AACR 2021：NX-1607治疗结直肠癌和三阴性乳腺癌，临床前研究效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4122082e0e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552030, encodeId=69da1552030b7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2021：抗CD47抗体AO-176治疗实体瘤和多发性骨髓瘤，临床前试验取得积极结果, objectType=article, longId=208262, objectId=b4f5208262d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4f5208262d5, replyNumber=0, likeNumber=91, createdTime=2021-03-13, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4f5208262d5, moduleTitle=AACR 2021：抗CD47抗体AO-176治疗实体瘤和多发性骨髓瘤，临床前试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4f5208262d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552029, encodeId=cfdc15520291e, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率, objectType=article, longId=196693, objectId=dce7196693fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dce7196693fd, replyNumber=0, likeNumber=58, createdTime=2020-06-30, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dce7196693fd, moduleTitle=AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dce7196693fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552028, encodeId=f67415520283f, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, objectType=article, longId=196545, objectId=5a8619654517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a8619654517, replyNumber=0, likeNumber=52, createdTime=2020-06-28, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a8619654517, moduleTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a8619654517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552027, encodeId=0589155202e1a, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, objectType=article, longId=196499, objectId=fcb619649997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb619649997, replyNumber=0, likeNumber=80, createdTime=2020-06-27, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb619649997, moduleTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcb619649997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552026, encodeId=0dc0155202602, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗, objectType=article, longId=196482, objectId=3e9419648230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e9419648230, replyNumber=0, likeNumber=66, createdTime=2020-06-27, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e9419648230, moduleTitle=AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e9419648230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552025, encodeId=f4b4155202578, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据, objectType=article, longId=196313, objectId=dbde196313ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbde196313ba, replyNumber=0, likeNumber=75, createdTime=2020-06-25, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbde196313ba, moduleTitle=AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbde196313ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552024, encodeId=a6141552024e0, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=2020 AACR：多功能溶瘤病毒BT-001对实体瘤具有强大活性, objectType=article, longId=194260, objectId=89fa194260ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89fa194260ac, replyNumber=0, likeNumber=61, createdTime=2020-05-18, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89fa194260ac, moduleTitle=2020 AACR：多功能溶瘤病毒BT-001对实体瘤具有强大活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89fa194260ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552023, encodeId=b6ff15520230c, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果, objectType=article, longId=193387, objectId=c66b19338e62, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c66b19338e62, replyNumber=0, likeNumber=70, createdTime=2020-05-04, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c66b19338e62, moduleTitle=AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c66b19338e62)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552022, encodeId=e4a91552022f8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, objectType=article, longId=193348, objectId=1c5c193348ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5c193348ad, replyNumber=0, likeNumber=66, createdTime=2020-05-03, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5c193348ad, moduleTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5c193348ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AACR

2020-05-29

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR重磅之KGOG 3046/TRU-D：度伐利尤单抗和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的II期研究

2022-04-12

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验

2022-04-12

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验

2022-04-12

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR重磅：在化疗的基础上加用阿德雷利单抗可明显改善广泛期SCLC的一线治疗

2022-04-12

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

2022-04-12

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果

2022-04-12

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR重磅：高基因扩增和肿瘤突变负荷组合作为接受替雷丽珠单抗治疗患者的泛癌生物标志物

2022-04-12

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究

2022-04-12

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR | 我国学者：97.17%的人至少是一种癌症的高风险人群，但坚持健康生活方式可明显降低风险!

2021-08-06

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR年会：新辅助免疫治疗将NSCLC患者的病理完全反应率提高12倍！

2021-04-15

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2021：NX-1607治疗结直肠癌和三阴性乳腺癌，临床前研究效果显著

2021-03-13

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2021：抗CD47抗体AO-176治疗实体瘤和多发性骨髓瘤，临床前试验取得积极结果

2021-03-13

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率

2020-06-30

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率

2020-06-28

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用

2020-06-27

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗

2020-06-27

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据

2020-06-25

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

2020 AACR：多功能溶瘤病毒BT-001对实体瘤具有强大活性

2020-05-18

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果

2020-05-04

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）

2020-05-03

科室
- - 订阅+
  - 更多科室
工具
服务